AG & IM in CA Stomach Protocol
Launched by CHINESE UNIVERSITY OF HONG KONG · Dec 1, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the AG & IM in CA Stomach Protocol, is looking at how well different methods can predict the risk of developing gastric cancer, which is cancer of the stomach. The study is currently recruiting participants who are 40 years and older and will involve two groups: one group includes patients who have been newly diagnosed with stomach cancer or have a history of high-grade dysplasia (a serious condition that can lead to cancer), while the other group consists of individuals with no previous history of stomach issues.
If you or a family member are interested in participating, you would need to undergo an elective upper gastrointestinal endoscopy, a procedure to look inside the stomach. However, this trial is not for everyone; for example, if someone has had stomach surgery in the past or certain blood disorders, they wouldn't be eligible. Participants can expect to help researchers understand better ways to assess the risk of gastric cancer, potentially leading to improved prevention strategies in the future. Your involvement could be vital in helping improve care for patients at risk of gastric cancer.
Gender
ALL
Eligibility criteria
- • Two groups of patients would be recruited in this case control study.
- • 1. Gastric neoplasia group Patients with newly diagnosed or history of cancer of stomach or gastric high grade dysplasia.
- • 2. Control group Patients with no prior history of gastric dysplasia or cancer
- Inclusion criteria:
- • 1. Age 40 or above
- • 2. Undergo elective upper gastrointestinal endoscopy
- Exclusion criteria:
- • 1. Patients with history of gastrectomy
- • 2. Patients with severe thrombocytopenia (Platelet count \<50) or coagulopathy (INR \> 1.5 or on anticoagulation)
- • 3. Contraindication to upper gastrointestinal endoscopy
- • 4. Allergy towards sedative agents (Midazolam / Diazepam) or local anaesthetic spray (Lignocaine)
- • 5. Patients who cannot give informed consent
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Singapore, , Singapore
Osaka, , Japan
Bangkok, , Thailand
Patients applied
Trial Officials
Hon Chi Yip
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials